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Improvement of breast-cancer detection through the identiﬁcation of potential cancer biomarkers is considered as a promising
strategy for eﬀective assessment of the disease. The current study has used nonequilibrium pH gradient electrophoresis with sub-
sequent analysis by mass spectrometry to identify protein alterations in invasive ductal carcinomas of the breast from Tunisian
women. We have identiﬁed multiple protein alterations in tumor tissues that were picked, processed, and unambiguously assigned
identities by matrix-assisted laser desorption/ionization-time of ﬂight mass spectrometry (MALDI-TOF). The proteins identiﬁed
spanawiderangeoffunctionsandarebelievedtohavepotentialclinicalapplicationsascancerbiomarkers.Theyincludeglycolytic
enzymes, molecular chaperones, cytoskeletal-related proteins, antioxydant enzymes, and immunologic related proteins. Among
these proteins, enolase 1, phosphoglycerate kinase 1, deoxyhemoglobin, Mn-superoxyde dismutase, α-B-crystallin, HSP27, Raf
kinase inhibitor protein, heterogeneous nuclear ribonucleoprotein A2/B1, coﬁlin 1, and peptidylprolyl isomerase A were overex-
pressed in tumors compared with normal tissues. In contrast, the IGHG1 protein, the complement C3 component C3c, which are
two newly identiﬁed protein markers, were downregulated in IDCA tissues.
Copyright © 2008 Maria Kabbage et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Breast cancer remains one of the leading causes of death
among women worldwide. The incidence rate of this malig-
nancy is steadily rising in developing countries. It is expected
to account for 31% of all new cancer cases among women in
USA [1]. In Tunisia, the incidence of breast cancer is approx-
imately 19 new cases per 100000 women per year [2].
Invasive carcinomas where the basement membrane is
totally or partially destroyed represent 70–80% of all breast
cancer and include more than 10 diﬀerent types. Among
these, inﬁltrating ductalcarcinomas(IDCA) are themost ag-
gressive forms and have a poor prognosis [3].
Nowadays, improvement of breast-cancer detection at
its early stage through the identiﬁcation of selective di-
agnostic biomarkers and targets for therapeutic interven-
tion is of critical importance. Alterations that occur in dis-
ease versus normal tissues at either the gene or protein
l e v e lh a v eb e e nr e g a r d e da sa na p p r o p r i a t ew a yt oi d e n t i f y
such markers of pathologies. In biomedicine, proteomics,
with the recent advances in mass spectrometry, is consid-
ered as a powerful analytical method for deciphering pro-
tein expression alterations as a function of disease progres-
sion [4]. Recently, proteomics-based analyses of breast tis-
sue lysates have resulted in the ﬁnding of a number of po-
tential tumor biomarkers providing, therefore, a basis for a2 Journal of Biomedicine and Biotechnology
better understanding of the intracellular signalling pathways
leading to breast-cancer development and progression [3],
and eventually serving as diagnostic and prognostic mark-
ers [5]. Probably the most widely used proteomic technol-
ogy is the identiﬁcation of alterations in protein expres-
sion between two diﬀerent samples through comparative
two-dimensional gel electrophoresis (2-DE) which provides
high-resolution separation of proteins and oﬀers a power-
ful method for their identiﬁcation and characterization. Ac-
tually, there is no universal 2-DE method that can be ap-
plied for all types of samples investigated, and protocols
must be optimized and adapted according to the types of
tissues and proteins of interest. It is also crucial to min-
imize protein alterations and degradations that could re-
sult in artifactual spots and to improve solubilization pro-
cedures in order to avoid loss of proteins during extraction
[6].
Although 2-DE is a laborious method, it is still consid-
ered as the principal tool in proteomics since it is able to sep-
arate proteins according to two independent physicochemi-
calparameterswhichareisoelectricpointandsize,andalsoit
provides the highest resolution in the separation of complex
protein mixtures [6]. 2-DE remains however, poor resolutive
in detecting proteins that are smaller than 10.000 Da or are
basic in charge [7]. An alternative method for the analysis of
basic proteins is found in the application of nonequilibrium
pH gradient electrophoresis (NEPHGE), which can provide
excellent resolution of basic proteins, oﬀering thus a promis-
ing approach for the discovery of tumor-related alterations
[8].
In a previous study, we have shown using IEF and mass
spectrometry that the levels of a number of proteins includ-
ing ﬁbrinogen-E, which is a potent antiangiogenic factor,
were dysregulated in IDCAs of the breast [9]. In the cur-
rent report, protein expression proﬁles issued from breast
IDCAs and their matched surrounding histologically nor-
mal tissues were examined by NEPHGE two-dimensional gel
electrophoresis and MALDI-TOF mass spectrometry. Using
this procedure, we established a NEPHGE-2-DE map of pro-
teins altered in IDCAs of the breast. By comparing 2-DE pro-
tein proﬁles, we report herein the identiﬁcation of several
proteins of interest dysregulated in tumor tissues. These al-
tered proteins belong to multiple cellular pathways and may
have a pathological role in breast carcinogenesis.
2. MATERIALS AND METHODS
2.1. Sampleprocessing
Breast tumor samples (n = 10) were selected from patients
living in the middle coast of Tunisia (median age at diagnosis
of 50 years) and classiﬁed as inﬁltrating ductal carcinomas.
Breast tumors were obtained with informed consent accord-
ing to protocols approved by the institutional review boards
of the respective hospitals. Carcinomas were pathologically
staged according to the TNM (Tumors, Nodes, Metastasis)
classiﬁcationsystemofUICC[10].Histologicalgradewasas-
sessed according to the modiﬁed SBR grading system [11].
All the tumors investigated were classiﬁed as T2/N0 and
the grade of the tumors was G3. Breast tumors and sur-
rounding histologically normal tissues were collected at the
time of surgery and analyzed by histopathology. Areas of
tumor were chosen after assessment by cryostat sectioning.
The ﬁrst, middle, and last sections were stained with hema-
toxylin and eosin, and examined by a pathologist to ensure
that at least 70% of the tissue sections used for the pro-
teomic study contained tumor cells. The nontumor tissues
wereconﬁrmedbycryostatsectionbeforeproteinextraction.
For proteomic analyses, tissue sections veriﬁed histologically
were suspended and homogenized in 250μL of 2-DE analy-
sis buﬀer: 7M urea, 2M thiourea, 4% CHAPS, 0.5% DTT,
and 2% ampholytes (1 part pH 3/10, 1 part pH 5/7, 2 parts
pH 6/8). The clear supernatant issued after centrifugation of
the homogenate at 12500g for 15 minutes was transferred to
a sterile microcentrifuge tube and immediately subjected to
2-DE analysis.
2.2. NonequilibriumpHgradientelectrophoresis,
IsoelectrofocalizationandSDS-PAGE
Protein contents were determined according to the proce-
dure described by Bradford and modiﬁed by Ramagli and
Rodriguez [12]. Bovine serum albumin (Fraction V, Sigma)
was used as a standard. Analytical 2-DE was carried out in a
BioRad system (Miniprotean II). Equal amounts of proteins
(100μg )i s s u e df r o mt u m o ro rn o n t u m o rb r e a s tt i s s u e sw e r e
appliedtotheﬁrstdimensionandatleastthreeNEPHGEgels
were run for each sample. NEPHGEhas been used to resolve
basic proteins as described earlier [8]. IEF was performed as
described previously [9]. For each experiment, extraction of
proteins, solubilization, NEPHGE, and SDS-PAGE were car-
ried under similar conditions for the tumor and nontumor
tissues. Electrophoresis was performed in triplicate for each
pair of samples to ensure reproducibility. The alterations re-
ported in the current study were retained after 2-DE analysis
of protein extracts issued respectively from diﬀerent frozen
sectionsofthe10tumorandnontumorsamplesinvestigated.
The reproducibility was about 85% or more which reﬂected
the small variances between samples or running.
2.3. Gelstaining
After separation, the proteins were visualized by a sensitive
colloidal Coomassie G250 stain [13]. The dye solution con-
tained 17% (w/v) ammonium sulfate, 3% (v/v) phosphoric
acid, 0,1% (w/v) Coomassie G250, and 34% (v/v) methanol.
The staining solution was changed once after 12 hours stain-
ing and the gel slabs subjected to a 24-hour cycle for in-
creasing dye deposition on low-abundance proteins. The de-
tection was then increased by placing the gel into 1% v/v
acetic acid for producing a better contrast between spots and
gel. Coomassie stained gels were scanned and spot detec-
tion and quantiﬁcation were carried out using PDQuest 2-D
software version 7.2 (Biorad). Proteins with signiﬁcant and
reproducible changes between tumor and nontumor tissues
were considered as diﬀerentially expressed. The abundance
of each protein was estimated by the percentage volume. The
individual spot volumes were normalized by dividing theirMaria Kabbage et al. 3
optical density (OD) volumes by the total OD values of all
the spots present in the gel and expressed as % vol. The sig-
niﬁcanceofexpressionbetweentumorandnontumortissues
was estimated by student’s t-test, P<. 05.
2.4. Spotpickingandin-geldigestion
Picked spots were washed with 100μLo f2 5m MN H 4HCO3
and dehydrated with 100μL of acetonitrile (ACN). This op-
eration was repeated twice and the pieces of gel were dried
under vacuum for 10 minutes. Reduction was achieved by
1-hour treatment with 10mM DTT in NH4HCO3 buﬀer
(100μL) at 56
◦C. After discarding the DTT solution, alky-
lation reaction was performed by the addition of 100μL
of 25mM iodoacetamide in 25mM NH4HCO3 buﬀer for 1
hour at room temperature, protected from light. Finally, the
excised gel pieces were again washed 3 times for 5 minutes
with25mMNH4HCO3 andACNalternately.Gelpieceswere
completelydriedundervacuumbeforetrypticdigestion.The
dried gel volume was evaluated (about 1 to 2μL) and 3 vol-
umes of trypsin (Promega, V5111), 12.5ng/μL, in 25mM
NH4HCO3 buﬀer (freshly diluted), were added. The diges-
tion was performed at room temperature overnight. After-
wards,5μLof35%H2O/60%ACN/5%HCOOHwereadded
and the mixture is sonicated for 30 minutes and centrifuged
in order to extract tryptic peptides.
2.5. ProteinidentiﬁcationbyMALDI-TOF-MS
Mass measurements were carried out on a BIFLEX III
MALDI-TOF (Bruker, Daltonics, Bremen, Ge) equipped
with the SCOUT high-resolution optics with X-Y multisam-
pleprobeandgridlessreﬂector.Thisinstrumentwasusedata
maximum accelerating potential of 19kV (in positive mode)
and was operated in reﬂector mode. A saturated solution of
α-cyano-4-hydroxycinnamic acid (Sigma, Saint Louis, MO)
in acetone was used as a matrix. A ﬁrst layer of ﬁne ma-
trix crystals was obtained by the spreading and fast evapo-
ration of 0.5μL of matrix solution. On this ﬁne layer of crys-
tals, a droplet of 0.5μL of aqueous HCOOH (5%) solution
was deposited. Afterwards, 0.5μL tryptic digest were added
and mixed to a second dried under vacuum. The sample was
washed once by applying 0.7μL of aqueous HCOOH (5%)
solution on the target and then ﬂushed after a few seconds.
In positive mode, internal calibration was performed with
tryptic peptides coming from autodigestion of trypsin, with
respectively monoisotopic masses at m/z = 842.510 and m/z
= 2211.105. Monoisotopic peptide masses were assigned and
used for databases searches. For the mass measurements, up
to 1 missed tryptic cleavage and optional methionine oxida-
tion were considered. In most cases, the mass accuracy was
less than 50ppm, a value which is generally considered ad-
equate for achieving statistically signiﬁcant results for pro-
tein identiﬁcation. These ﬁles were then fed into the search
engine MASCOT (Matrix Science, London, UK). The data
were searched against NCBI nonredundant protein sequence
database.
2.6. Immunohistochemistry(IHC)
IHC analysis of α-B crystallin was performed on formalin-
ﬁxed, paraﬃn-embedded sections of IDCA breast tumors.
Standard indirect immunoperoxidase procedures were used
for detection of α-B crystallin. Brieﬂy, ﬁve-micrometer sec-
tions were deparaﬃnized in toluene and subsequently hy-
drated with graded ethanol, and rehydrated in water. Slides
were microwaved in 0.01M citrate buﬀer at pH 6.0 for 20
minutes at 750W. Thereafter, sections were rinsed thor-
oughly with water and placed in a Tris–buﬀered saline (TBS)
solution (0.05M Tris-HCl pH 7.6, 1.15M NaCl). Endoge-
nous peroxidase activity was blocked with hydrogen perox-
ide solution for 7 minutes and sections were rinsed gently
with TBS. Sections were then incubated at 4◦C overnight
with the antibody against α-B crystallin (AB1546, Chemi-
con) at a dilution of 1 : 1000. After rinsing in TBS, sec-
tions were incubated with the secondary antibody, Dako-
Cytomation EnVision+Dual Link System Peroxydase (Dako-
Cytomation, Glostrup, Denmark), for 30 minutes. Sections
were washed 2 times with TBS, followed by application of
thediaminobenzidinesubstratepackaccordingtothemanu-
facturer’s instructions (DakoCytomation), yielding a brown-
colored signal. Finally, tissue sections were counterstained
withhematoxylinandmounted.Standardizationoftheincu-
bation and development times allowed an accurate compar-
ison of expression levels in all cases. IHC staining was eval-
uated by two independent pathologists for staining intensity.
Cases were considered positive if 10% or more of the tumor
cells showed unequivocal immunoreactivity.
3. RESULTS
In the current study, we have used an NEPHGE-2-DE pro-
tocol for the analyses of basic proteins, and using this pro-
cedure established an NEPHGE-2-DE map of proteins al-
tered in IDCAs of the breast. Since NEPHGE is stopped be-
fore equilibrium is attained, accurate experimental estima-
tionofthepIsofthedysregulatedproteinscannotbemadeby
this method. Table 1 depicts the theoretical isoelectric points
(pIs) and molecular weights of altered proteins in tumor tis-
sues,manyofwhicharebasic.Inourhands,whileNEPHGE-
2-DE allowed the resolution of basic proteins, IEF-2-DE re-
sulted as expected in the stacking of most of basic proteins at
the basic end, even if the IEF pH gradient has been extended
to higher pH values.
In our hands, a comparison of the 2-DE protein patterns
obtained at constant voltages of 400V for 3 hours (1200V-
Hr) or 4 hours (1600V-Hr) showed an optimal resolution
of basic proteins at 1200V-Hr while preventing basic pro-
teins from running oﬀ the basic end of the gels. By using
the protein extraction procedure listed in Section 2,a na v -
erage amount of 100μg of total proteins from each sam-
ple was used in 2-DE investigations. Figure 1 displays elec-
trophoresis patterns of proteins from tumor and nontumor
samples subjected to NEPHGE-2-DE electrophoresis. By us-
ing this procedure, we have found that the majority of the
proteins displayed were not diﬀerent in abundance between
normal and cancer tissues. Protein alterations occurring in4 Journal of Biomedicine and Biotechnology
Table 1: Results of MALDI-TOF mass spectra and database searching for protein identiﬁcation.
Identiﬁed
proteins
Spot(a)
number
Mr(kDa)/
pI(b)
Access
N◦(c)
Peptides
matched
Relative(d) volume (%)
Mass
accuracy
(ppm)
Sequence
coverage %
Reported
function
NT
Complement
component C3c
(chainD)
1 71317/6.82 78101272 36 0.085 ± 0.015 0.02 ±0.007 45 64 Immune
response
IGHG1 protein 2 45286/8.63 44890623 9 0.121 ± 0.001 0.021 ±0.008 42 27 Immune
response
IGHG1 protein 3 45286/8.63 44890623 9 0.142 ± 0.008 0.041 ±0.006 43 29 Immune
response
IGHG1 protein 4 45286/8.63 44890623 7 0.12 ±0.004 0.019 ±0.009 50 24 Immune
response
IGHG1 protein 5 45286/8.63 44890623 7 0.101 ± 0.006 0.014 ±0.005 50 24 Immune
response
IGHG1 protein 6 45286/8.63 44890623 7 0.095 ± 0.007 0.017 ±0.006 50 24 Immune
response
Carbonic
anhydrase 1
7 28909/6.59 4502517 13 0.081 ± 0.01 0.018 ±0.009 72 72 metabolic
enzyme
Enolase1 8 47481/7.01 4503571 30 0.012 ± 0.001 0.131 ±0.006 41 62 Glycolytic
enzyme
phosphoglycerate
kinase 1 9 44973/8.30 48145549 28 0.015 ± 0.007 0.108 ±0.03 60 58 Glycolytic
enzyme
Deoxy
hemoglobin
(ChainD)
10 15928/7.14 27574253 11 0.018 ± 0.004 0.123 ±0.006 49 79 O2/CO2
transport
Deoxy
hemoglobin
(ChainD)
11 15928/7.14 27574253 11 0.022 ± 0.002 0.131 ±0.002 49 80 O2/CO2
transport
Manganese
superoxide
dismutase
12 22290/6.86 2780819 9 0.019 ± 0.006 0.075 ±0.001 50 57 Anti-oxidant
enzyme
Alpha
B-Crystallin
13 20146/6.76 13937813 11 0.022 ± 0.001 0.097 ±0.014 57 56 Chaperone
Raf Kinase
inhibitor protein
14 16068/8,81 4261934 9 0.019 ± 0.008 0.132 ±0.015 45 54 Signaltrans-
duction
Peptidyl-
prolylisomerase A 15 18228/7,68 13937981 13 0.02 ±0.007 0.109 ±0.001 67 59 Immuno-
philin
Peptidyl-
prolylisomerase A 16 18228/7,68 13937981 14 0.011 ± 0.004 0.102 ±0.005 67 60 Immuno-
philin
Coﬁlin1 17 18719/8.22 15147369 8 0.018 ± 0.008 0.112 ±0.012 35 45 Actinturnover
HSP27 18 22427/7.83 662841 12 0.021 ± 0.001 0.117 ±0.003 48 51 Chaperone
HSP27 19 22427/7.83 662841 16 0.014 ± 0.008 0.097 ±0.005 48 67 Chaperone
hnRNPA2/B1
isoform A2 20 36041/8.67 4504447 21 0.015 ± 0.007 0.141 ±0.021 35 53 Several
functions
(a) Index in the reference gel (Figure 1).
(b)Expected Mr and pI which were calculated on the complete sequences.
(c)Accession number in NCBI.
(d)The individual spot volumes were expressed as a percentage of the total volume in all of the spots present in the gel. N: nontumor tissue; T: tumor tissue.Maria Kabbage et al. 5
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Figure 1: 2-DE pattern of proteins from tumor and nontumor samples resolved by NEPHGE 2-DE and listed in Table 1. Proteins dysreg-
ulated in tumor tissues (T) as compared to nontumor tissues (N) are highlighted with arrows. The numbers indicated correspond to those
given in Table 1. (1)–(7): proteins downregulated in tumor tissues; (8)–(20): proteins upregulated in tumor tissues. (1) complement com-
ponent C3c; (2)–(6) IGHG1 protein isoforms; (7) carbonic anhydrase 1; (8) enolase 1; (9) phosphoglycerate kinase 1 (PGK1); (10), (11)
hemoglobin; (12) MnSOD; (13) α-B crystallin; (14) Raf kinase inhibitor protein; (15), (16) peptidylprolylisomerase A (PPIA); (17) coﬁlin
1; (18), (19) HSP27; (20) hnRNP A2/B1.
the tumor and normal tissues are highlighted with arrows
(Figure 1). Among the proteins identiﬁed, the levels of 13
proteins were increased in the tumor samples, while 7 pro-
teins were rather observed at higher amounts in the non-
neoplastic breast tissues. These alterations were regarded as
serious alterations occuring between tumor and nontumor
tissues. Altered proteins were subsequently excised and sub-
jected to in-gel tryptic digestion and MALDI-TOF analy-
ses. This procedure allowed the unambiguous identiﬁcation
of the proteins investigated. Figure 2 shows an example of
MALDI-TOF peptide mass ﬁngerprints of the tryptic di-
gests corresponding to alpha B-crystallin. Table 1 lists all of
the proteins identiﬁed. A wealth of evidence suggests that
most of these dysregulated proteins are closely related to
neoplastic transformation. These proteins could be classiﬁed
on the basis of their functions into stress-related, chaper-
oning proteins, cytoskeletal-related proteins, metabolic en-
zymes, and other molecules related to immunological re-
sponses. Some of these alterations depicted in Figure 1 in-
volve co-upregulations of glycolytic enzymes (enolase1, spot6 Journal of Biomedicine and Biotechnology
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Figure 2: MALDI-TOF peptide mass ﬁngerprints of the tryptic di-
gests corresponding to alpha B-crystallin. The matched peptide se-
quences are underlined.
8; phosphoglycerate kinase 1, spot 9) in tumor tissues, as
well as, proteins involved in antioxidation pathways includ-
ingpeptidylprolylisomeraseA(spots15,16),whichhasbeen
reported to protect cells against oxidative stress and man-
ganese superoxyde dismutase (Mn-SOD, spot 12). Two other
newly identiﬁed proteins related to immunologic responses
present at lower levels in tumor tissues include complement
component C3c (spot 1) and IGHG1 (spots 2–6).
More interestingly, the levels of Raf kinase inhibitor pro-
tein (spot 14) were found to be overexpressed in cancer
tissues indicating a possible special pathological role for
this protein in breast carcinogenesis. Other alterations more
represented with respect to the IDCA tissues include heat
shockproteins(HSP27,spots18,19)andα-B-crystallin(spot
13). Subsequent immunohistochemical staining against α-B-
crystallin has also been performed (Figure 3). Expression of
α-B-crystallin was noted in all cases investigated and positiv-
ityhasbeenretrievedin80to90%oftumorcells.Thesignals
detected in tumor cells were strong whereas epithelial cells of
the normal tissues express lower levels of this protein.
4. DISCUSSION
Proteomics-based studies are increasingly used to examine
cancer-related changes in protein expression. Such protein
alterations may eventually contribute to increase our under-
standing of the disease pathogenesis as well as in the devel-
opment of eﬀective strategies for diagnosis and treatment.
The present study aims to investigate protein alterations in
IDCAs of the breast using an NEPHGE-2-DE procedure. As
shown in this comparative analysis, certain speciﬁc proteins
were dysregulated in IDCAs compared with their paired nor-
mal samples. These altered proteins were subsequently ana-
lyzed by mass spectrometry and unambiguously assigned on
the basis of MALDI-TOF spectra obtained after trypsin di-
gestion (Table 1). The proteins identiﬁed span a wide range
offunctionsandmayhaveavalueasdiagnosticandprognos-
tic biomarkers for breast cancer. Among the proteins identi-
ﬁed, we established that there is a decreased expression of
IGG1 and complement component C3c proteins in breast-
tumor tissues. These alterations related to immunologic re-
sponses constitute novel identiﬁcations that were not previ-
ously reported as potential markers of IDCA breast tumors.
As shown in Figure 1, the IGG1 proteins were observed as
multiple protein spots with diﬀerent isoelectric points and
similar molecular weights. As displayed in NEPHGE-2-DE
gels, these proteins appeared intact as judged by their appar-
ent molecular mass and were closely associated with nonma-
lignant tissues.
Consistent with our ﬁndings, several studies have shown
that malignant diseases of various tissue origin are associ-
ated with a shift in the IGG subclass distribution. For exam-
ple, the decrease of IGG1 serum levels reported in colorec-
tal cancer has been considered as an early tissue nonspeciﬁc
indicator of malignant transformation that could be useful
in the primary diagnosis of colorectal tumors [14]. Such al-
terations were recently reported to occur in colorectal ade-
nocarcinomas and normal colorectal tissues using suppres-
sion subtractive hybridization techniques [15]. A highly re-
duction of the percent of IGG1 in several gynecologic malig-
nant diseases has also been correlated with early carcinoma
stages and was found as a reliable marker that discriminates
between cancer patients and controls with a speciﬁcity rang-
ing between 90 and 100% [16]. The reduction in IGG1 plas-
matic levels has also been reported as a highly sensitive tu-
mormarkerfordetectingprimaryandmetastaticsquamous-
cell carcinomas of the head and neck [17], and was signif-
icantly correlated with early stages of invasive breast cancer
[18]. Up to now, such alterations in IGG1 levels were found
with neoplastic diseases only and may likely reﬂect changes
in the host’s immune system linked to the presence of ma-
lignant tumors. Recent data unveiled that malignant tumors
of various tissues lead to irregularity of the biosynthesis of
IGG1andIGG2byaﬀectingtheirmessengerRNAlevelsinB-
cell lymphocytes [19]. It has been hypothesized in this con-
text that cancer cells may aﬀect the synthesis of such IGG
subclasses by acting on the T-helper 1/T-helper 2 ratio in
the host, and, consequently, aﬀect the level of speciﬁc cell-
derived cytokines implicated in human IGG synthesis [20].
Our observation of underexpression of IGG1 in IDCAs with
regard to nontumor tissues may therefore, indicate a simi-
lar tumor-associated mechanism by which cancer cells aﬀect
IGG1 synthesis. Further investigations are needed however,
to elucidate how malignant breast tissues may interfere with
theT-cellmediatedregulationofIGGsuclasses.Interestingly,
downregualtion of IGG1 levels and concomitant downregu-
lation of complement component C3c were observed in our
results. To our knowledge, no studies have yet reported the
decreased expression of this protein in IDCAs of the breast.
The diﬀerential tissue expression of this complement protein
provides evidence for the involvement of anti-inﬂammatory
processes in IDCA tissues and may indicate a selective adap-
tation by breast tumors to escape elimination by antitumor
immune responses. Until recently, several studies with nor-
mal and malignant tissues have disclosed the presence ofMaria Kabbage et al. 7
(a) (b)
(c) (d)
Figure 3: Overexpression of α-B crystallin in inﬁltrating ductal carcinoma tissues of the breast. Formalin-ﬁxed, paraﬃn-embedded sec-
tions were immunostained with rabbit polyclonal antibody against α-B crystallin. Tissues were stained with hematoxylin and viewed by
light microscopy. A strong staining (brown) in tumor cells (T) has been observed, whereas α-B crystallin was expressed at lower levels in
normal epithelial cells. (a) α-B crystallin expression in IDCA tissues (200x magniﬁcation), (b)-(c) α-B crystallin expression in IDCA (400x
magniﬁcation), (d) α-B crystallin expression in nontumor tissues (400x magniﬁcation).
s e v e r a li m m u n ee s c a p es t r a t e g i e sb yw h i c hc a n c e rc e l l sp r o -
tect themselves from the lytic action mediated by comple-
ment. Several evasion strategies to complement attack have
been reported in malignant cells and include complement
protective proteins (CD46, CD55, CD59), membrane pro-
teasesreportedtoconfercomplementresistancebyremoving
cell-bound complement components such as C3 and tumor
secreted complement inhibitors [21]. Such inhibitory mech-
anisms, often upregulated in tumors, are thought to increase
resistance to complement in malignant tissues through inhi-
bition of serum complement activation upon cancer cells. A
previous study using a rat model of human breast cancer un-
veiledthatinhibitorsofcomplementactivationmayfacilitate
tumor growth and enhance tumorigenicity of breast-cancer
cells by inhibiting C3 deposition [22]. The present downreg-
ulation of complement C3 component C3c in IDCAs may,
therefore, indicate the involvement in breast tumors of simi-
lar complement inhibitory mechanisms.
The Raf kinase inhibitor protein (RKIP) known also
as phosphatidylethanolamine binding protein-1 (PEBP-1) is
anotherbasicproteinthathasbeendescribedasbeingacom-
ponent of the important feedback inhibition in G-protein
coupled signal transduction [23]. It is also involved in the
regulation of the NF-kappa B pathway and is associated
with resistance to TNF-α by inhibiting activation of the Raf
1/MEK/extracellular signal regulated kinase pathway, JNK,
and phosphatidylethanolamine (PE) externalization, which
is an early symptom of apoptotic cell death resulting in the
total loss of asymmetric distribution of aminophospholipids
in the plasma membrane bilayer [24, 25]. It has also been
reported that overexpressing a new member of the PEBP
family (PEBP-4) correlates with both a decreased TNF-α-
induced PE externalization and resistance to TNF-α-induced
apoptosis [26]. Interestingly, recent data revealed that silenc-
ing of PEBP-4 expression in MCF-7 breast-cancer cells pro-
motes TNF-α-induced apoptosis, as well as TNF-α-induced
ERK and JNK activation making this PE binding protein as
a promising target for the treatment of breast cancer [27].
Overall, the present ﬁndings in IDCAs of the breast might
reﬂect the previously reported results for the relation be-
tween PE-binding proteins and TNF-related apoptosis path-
way. The present increase in RKIP may confer breast-cancer
cells to an advantage for survival and proliferation.
From our results, the high abundance of hemoglobin in
breasttumorscouldnotbeconsideredasareliableparameter
for distinguishing between tumor and nontumor tissues. In-
deed, the relationship between tissue hemoglobin levels and
breast tumors appears indirect and indicates rather an en-
hanced blood supply to the tumor. Since tumor angiogen-
esis is a crucial arbiter of breast-cancer growth/metastasis,
this higher level of hemoglobin is consistent with the higher
vascular density of growing tumors compared with normal
tissues.
Besides these alterations, the concomitant upregula-
tion of two other stress-related proteins (peptidylpro-
lylisomerase A, MnSOD) was observed in IDCAs. The8 Journal of Biomedicine and Biotechnology
peptidylprolylisomerase A also called cyclophilinA (CypA)
is described as being involved in protein folding and cat-
alyzes the cis/trans-isomerization of peptide bonds preced-
ingaprolineresidue.Itissecretedbycellsinresponsetoboth
inﬂammatory stimulation and oxidative stress [28]. Our ob-
servation on the expression of CypA is consistent with the
published results from studies on other cancers. Overexpres-
sion of CypA has been reported in colorectal carcinomas in
comparisontonormalmucosaandisinvolvedinlung-tumor
growth by aﬀecting proliferation and apoptosis [29]. A re-
centstudyhasshownthatbothCypAanditsreceptorCD147
areupregulatedinhumanpancreaticadenocarcinomascom-
paredtonormalpancreaticductalepithelium[30].Theseau-
thors pointed that CypA is a promoter of pancreatic tumor
growth and is involved in chemotaxis and cell signalling cas-
cades. The present ﬁnding reveals a similar correlation, im-
plyingthatbreastcarcinomasmayshareasimilarmechanism
of cell proliferation mediated by CypA. The MnSOD is a mi-
tochondrial enzyme that has been reported to protect cells
against oxidative stress by increasing the dismutation rate of
superoxide anion (O
−
2 )t oh y d r o g e np e r o x i d e( H 2O2)w h i c h
is then converted into water by catalase and glutathione per-
oxidase. The role of this antioxidant enzyme in carcinogene-
sisisstillhowevercontroversialandunclear.Infactalthough,
i th a sb e e nr e p o r t e dt os u p p r e s sa p o p t o s i sa n dp r o t e c tc e l l s
against several insults, under some circumstances, the Mn-
SOD may prevent cell proliferation [31]. Although further
studies are needed, the present elevation of MnSOD may in-
dicate that the antioxidant defense system has been stimu-
lated in invasive carcinomas of the breast, highlighting the
ability of tumor cells to prevent damage due to reactive oxy-
gen species.
Interestingly, the co-upregulation of two glycolytic en-
zymes, enolase 1 and phosphoglycerate kinase 1 (PGK-1)
also occurred in IDCA tissues. These enzymes are key com-
ponents of the glycolytic pathway that have shown a prior
relationship to cancer. Indeed, our observation of increased
expression of enolase 1 and PGK-1 is supported in vari-
ous tumor tissues and may relate to the increased require-
mentofbothenergyandproteinsynthesis/degradationpath-
ways during carcinogenesis [32]. This increased glycolytic
metabolism is also thought to regulate hypoxia-inducible
gene expression in solid tumor tissues and participates in an-
giogenesis [33].
The protein coﬁlin-1 also was identiﬁed as diﬀerentially
expressed between tumor and normal tissues. This protein
is recruited at the leading edge of cells where its activation
is essential for polarized migration. Coﬁlin-1 is directly im-
plicated in severing actin cytoskeleton ﬁlaments and regu-
lates the polymerization/depolymerization of actin during
cell migration [34]. It has been recently demonstrated that
coﬁlin expression is required for tumor cell invasion since
inhibition of coﬁlin activity in carcinoma cells inhibits cell
motility whereas increased expression correlates with en-
hanced cell migration [35]. More recently, Wang et al. [34]
have demonstrated that overexpression of coﬁlin-1 is neces-
sary for the activation of the coﬁlin pathway resulting in cell
motility, invasion and metastasis. This protein has also been
associated with melanoma cell invasion and migration via its
interaction with the αvβ3 integrin [36]. Overall, the current
ﬁndings support the recently identiﬁed role for coﬁlin activ-
ity and highlight its involvement in invasive lesions of the
breastasadeterminantfactorrequiredforcellmigrationand
invasion.
The molecular chaperone HSP27 and alpha B-crystallin,
which is a small heat shock protein (HSP) are two other dys-
regulated proteins in tumor tissues. In a previous investiga-
tion,wehavereportedthatthreeothermolecularchaperones
(GRP78, calreticulin, protein disulﬁde isomerase) are dif-
ferentially expressed in breast tumors [9]. The concomitant
upregulation of these HSPs together with alpha B-crystallin
and HSP27 is not surprising since chaperones are thought to
work cooperatively to fulﬁl their functions [37]. Due to the
capacity of HSPs to prevent stress-accumulated, unfolded,
and nascent protein aggregation, their expression has proven
to have important pathological implications such as cell pro-
liferation and disease prognosis [4]. The HSP27 is a molecu-
lar chaperone whose rate of synthesis increases many folds
in response to environmental stress and during malignant
transformation [38]. As shown in Figure 1, this protein ex-
ists as two distinct isoforms that were conﬁrmed by mass
spectrometry as HSP27 (Table 1). Although no evidence of
posttranslational alterations was pointed out, these isoforms
as reported in renal cell carcinomas might reﬂect phospho-
rylation or other posttranslational modiﬁcations [39]. In the
last years, the role of alpha B-crystallin in cancer pathology
has been widely discussed with regard to its potential onco-
genic role. Previous studies unveiled that this small HSP may
constitute a good target for modulating cell death pathways
[40]. Its expression has been shown to inhibit both the mito-
chondrial and the receptor death activation pathways of cas-
pase 3 [41] and correlates with TRAIL resistance in a panel
of cancer cell lines [42]. This protein may also be an inter-
esting molecular target for exploring the evolution and the
origin of breast tumors since higher alpha B-crystallin lev-
els were reported in ductal carcinoma in situ, which is an
earliest form of detectable breast cancer [5]. The data re-
ported herein appear to conﬁrm this for invasive carcino-
mas as well. Although further studies are needed to answer
how this oncoprotein contributes to breast cancer, the data
reported herein highlight the importance of this molecular
chaperone in invasive carcinomas as a biomarker that may
play a distinctive role in the process of carcinogenesis.
5. CONCLUSION
In summary, our data have shown the value of using
an NEPHGE 2-DE based proteomic approach in identify-
ing potential molecular alterations and targets for breast-
cancer therapeutics and diagnostics. We have identiﬁed a
number of tumor-associated proteins including chaperones,
energy-producing enzymes, stress-related proteins, proteins
involved in apoptosis and cell motility, as well as alterations
highlighting changes in the host’s immune system linked to
the presence of malignant tissues. These protein variations
indicate that multiple cellular pathways are involved in the
process of breast carcinogenesis. Such alterations may helpMaria Kabbage et al. 9
to better understand the pathology of this disease and may
have potential clinical applications as cancer biomarkers.
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